KRASᴳ¹²ᶜ Mutation–Positive Advanced NSCLC

2021 Year in Review - Non–Small-Cell Lung Cancer - Lung Cancer

Lung cancer is the second most frequent cancer in both men and women, and the leading cause of cancer death on the globe.1 Non–small-cell lung cancer (NSCLC) accounts for approximately 84% of lung cancer cases.1 The majority of patients with NSCLC in the United States have advanced disease and a dismal prognosis.1

NSCLC has a high prevalence of mutations in the RAS viral oncogene family of proto-oncogenes, with the KRAS homolog being the most often mutated isoform.1 KRAS mutations are detected in 20% to 40% of NSCLC cases in Western cultures.2 They are more common in Western populations than in Asian populations, and more prevalent in smokers than nonsmokers.2

Despite the fact that KRAS mutations in NSCLC tumors have been detected for more than 30 years, they have long been regarded as “untreatable,” and until recently no licensed targeted therapy existed.2

We now have a better understanding of the complex interactions involved in the RAS family of signaling proteins thanks to the discovery of the switch II pocket on the surface of active and inactive forms of KRAS, which has led to the development of a number of promising direct KRASG12C inhibitors, such as sotorasib and adagrasib (MRTX-849).3 Clinical activity has been demonstrated for sotorasib and adagrasib monotherapy in previously treated patients with KRASG12C mutation–positive NSCLC; these findings have led to the development of new targeted therapeutic options.3

Sotorasib is a covalent KRASG12C inhibitor that binds to the switch II pocket within mutant KRAS, trapping it in an inactive form irreversibly and selectively.3 In the CodeBreaK 100 study, sotorasib monotherapy was tested in patients with previously treated, locally progressed, or metastatic cancers carrying a KRASG12C mutation.3 Findings from this study led to its regulatory approval in the United States in 2021. Adagrasib is another KRASG12C inhibitor in development.3

Although sotorasib and adagrasib have shown to be effective in treating individuals with lung adenocarcinomas and KRASG12C mutations, numerous uncertainties remain. What are the mechanisms of inhibitor resistance, and how may a greater understanding of these mechanisms help with patient selection or combination strategies?3

References

  1. Spira AI, Tu H, Aggarwal S, et al. A retrospective observational study of the natural history of advanced non-small-cell lung cancer in patients with KRAS p.G12C mutated or wild-type disease. Lung Cancer. 2021;159:1-9.
  2. Sebastian M, Eberhardt WEE, Hoffknecht P, et al; for the CRISP Registry Group. KRAS G12C-mutated advanced non-small cell lung cancer: a real-world cohort from the German prospective, observational, nation-wide CRISP Registry (AIO-TRK-0315). Lung Cancer. 2021;154:51-61.
  3. Reck M, Carbone DP, Garassino M, Barlesi F. Targeting KRAS in non-small-cell lung cancer: recent progress and new approaches. Ann Oncol. 2021;32:1101-1110.
Related Items
Third-Line Tyrosine Kinase Inhibitor Therapy Results in 16-Year Remission in a Patient with Stage IV Non–Small-Cell Lung Cancer
JHOP - August 2022 Vol 12, No 4 published on August 22, 2022 in Case Reports, Lung Cancer
2022 Midyear Review: Non–Small-Cell Lung Cancer
JHOP - Supplements published on July 21, 2022 in Lung Cancer
First-Line Sotorasib Shows Long-Lasting Responses in Metastatic NSCLC with KRAS Mutation
JHOP - June 2022 Vol 12, No 3 published on June 16, 2022 in AACR Highlights, Lung Cancer
Opdivo plus Platinum-Based Chemotherapy FDA Approved as First Neoadjuvant Treatment in Early-Stage NSCLC
JHOP - April 2022 Vol 12, No 2 published on May 3, 2022 in FDA Oncology Update, Lung Cancer, Checkpoint Inhibitors
Severe Adverse Events from Immune Checkpoint Inhibitor Therapy a Rare Concerning Side Effect
2021 Year in Review - Non–Small-Cell Lung Cancer published on December 29, 2021 in Lung Cancer
CodeBreaK 100 Trial Results Demonstrate Sotorasib Conveys Clinical Benefit Across NSCLC Patient Subgroups
2021 Year in Review - Non–Small-Cell Lung Cancer published on December 29, 2021 in Lung Cancer
NSAID Use with Immune Checkpoint Inhibitors Associated with Longer Overall Survival in NSCLC
2021 Year in Review - Non–Small-Cell Lung Cancer published on December 29, 2021 in Lung Cancer
The Effect of Various KRAS Mutations on NSCLC Susceptibility
2021 Year in Review - Non–Small-Cell Lung Cancer published on December 29, 2021 in Lung Cancer
Patterns of Biomarker Testing in Metastatic NSCLC in the Community Oncology Setting
2021 Year in Review - Non–Small-Cell Lung Cancer published on December 29, 2021 in Lung Cancer
Adagrasib Shows Promising Results in Pretreated KRAS Mutation–Positive NSCLC
2021 Year in Review - Non–Small-Cell Lung Cancer published on December 29, 2021 in Lung Cancer
© Amplity Health. All rights reserved.

Subscribe Today!

To sign up for our newsletter or print publications, please enter your contact information below.

I'd like to receive: